Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Conditions
- NSCLC Stage IV
- ALK Fusion Protein Expression
Interventions
- BIOLOGICAL: Peptide vaccine
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators